Allergan receives NICE recommendation for Truberzi

Allergan has announced that its irritable bowel syndrome therapy Truberzi has been recommended by the UK's National Institute of Health and Care Excellence (NICE).

A final appraisal determination has been issued by the regulator recommending that Truberzi be made available on the NHS in England and Wales for adults living with irritable bowel syndrome with diarrhoea (IBS-D).

This first-in-class oral medication can be administered twice daily to provide sustained relief from multiple symptoms of IBS-D, including pain, diarrhoea, urgency and bloating.

In two pivotal phase III trials, Truberzi demonstrated a significant reduction in the two most bothersome symptoms of IBS-D – abdominal pain and diarrhoea – with fast and sustained relief for more than six months.

Nicola Massey, country manager for Allergan in the UK and Ireland, said: "We look forward to the final appraisal determination being translated into final guidance and then being implemented across the health service."

IBS-D can be debilitating, with limited therapeutic options available for managing its chronic symptoms. It is associated with a high economic burden in direct medical costs, as well as indirect social costs such as absenteeism and lost productivity.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.